Literature DB >> 501568

Chronic amphetamine administration to cats: behavioral and neurochemical evidence for decreased central serotonergic function.

M E Trulson, B L Jacobs.   

Abstract

Chronic administration of amphetamine to cats (twice daily, in doses increasing from 5 to 15 mg/kg over a 10-day period) elicited a number of behaviors, e.g., limb flick and abortive groom, characteristic of the action of hallucinogenic drugs and dependent on a depression of central serotonergic neurotransmission. This drug treatment produced large decreases (-40 to -60%) in central nervous system serotonin (5-HT) and its major metabolite, 5-hydroxyindoleacetic acid (5-HIAA), when measured either 6 or 24 hr after the last amphetamine injection. The rate of limb flicking returned to a predrug level approximately 5 days after drug withdrawal, at which time 5-HT and 5-HIAA levels had returned to within 30 to 40% of base line. Both 5-HT and 5-HIAA returned to base-line levels within 14 days after drug withdrawal. Norepinephrine (NE), dopamine (DA) and DA metabolites were decreased 60 to 95% by chronic amphetamine treatment and showed little recovery within the 14 days after drug withdrawal. A second experiment examined the latency to onset of the behavioral and neurochemical changes with a constant dose of amphetamine (7.5 mg/kg, twice daily). Limb flicking was significantly increased above base-line levels following 3 days of amphetamine administration, at which time 5-HT and 5-HIAA levels were decreased 30 to 40%. NE, DA and DA metabolites were decreased approximately 50 to 90% by this treatment regimen. A third experiment examined the effects of a low dose of amphetamine (3.75 mg/kg), injected more frequently (every 6 hr for 6 days), to approximate the administration pattern in human amphetamine abuse. This treatment produced significant increases in limb flicking and abortive grooming on days 5 and 6 and resulted in 30 to 40% depletions of 5-HT and 5-HIAA. NE, DA and DA metabolites were decreased by approximately 50 to 90%. These data are discussed in relation to a role for serotonin in amphetamine psychosis and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 501568

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Behavioural tolerance to amphetamine and other psychostimulants: the case for considering behavioural mechanisms.

Authors:  C Demellweek; A J Goudie
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

2.  Selective (+)-amphetamine neurotoxicity on striatal dopamine nerve terminals in the mouse.

Authors:  G Jonsson; E Nwanze
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

3.  Abstinence from repeated amphetamine treatment induces depressive-like behaviors and oxidative damage in rat brain.

Authors:  Yi Che; Yong-Hua Cui; Hua Tan; Ana C Andreazza; L Trevor Young; Jun-Feng Wang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-01       Impact factor: 4.530

4.  Effect of chronic amphetamine administration on central dopaminergic mechanisms in the vervet.

Authors:  F Owen; H F Baker; R M Ridley; A J Cross; T J Crow
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

5.  A study on the acute effect of amphetamine on the urinary excretion of biogenic amines and metabolites in monkeys.

Authors:  L W Chuang; F Karoum; M J Perlow
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

6.  Behavioural and biochemical effects of chronic amphetamine treatment in the vervet monkey.

Authors:  R M Ridley; H F Baker; F Owen; A J Cross; T J Crow
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  Potentiation of d-amphetamine and L-dopa-induced acoustic startle activity after long-term exposure to amphetamine.

Authors:  L Kokkinidis; E P MacNeill
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.